Cabaletta Bio's Rese-cel Shows Sustained One-Year Responses in All Six Dermatomyositis Patients

• Cabaletta Bio announced new Phase 1/2 rese-cel results for presentation at ACR Convergence 2026 on November 8-9.
• Dermatomyositis patients maintained improvement without immunomodulators through one year; lupus nephritis patients achieved remission with biopsy evidence of reduced disease activity.
• Systemic sclerosis patients showed sustained improvement without immunomodulators through one year, including better lung function among those with interstitial lung disease.
• Safety findings across 71 patients supported a favorable benefit-risk profile, with mostly mild or no cytokine release syndrome.
• Registrational dermatomyositis trial results are expected in the second half of 2027, with a myositis biologics application planned for first-quarter 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001759138-26-000050), on November 09, 2026, and is solely responsible for the information contained therein.